



(51) International Patent Classification:

A61K 9/16 (2006.01) C07D 487/04 (2006.01)
A61K 31/437 (2006.01) A61P 1/00 (2006.01)
C07D 401/12 (2006.01) A61P 35/00 (2006.01)
C07D 403/12 (2006.01) A61P 35/02 (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/US2023/085459

(22) International Filing Date:

21 December 2023 (21.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/476,812 22 December 2022 (22.12.2022) US

(71) Applicant: **COGENT BIOSCIENCES, INC.** [US/US];
275 Wyman Street, 3rd Floor, Waltham, Massachusetts
02451 (US).

(72) Inventors: **BARNETT, Bradley**; 2579 Otter Ct.,
Lafayette, Colorado 80026 (US). **ROSINOVSKY, Elodie**;
22 Harrison Street, Maynard, Massachusetts 01754 (US).

SAHIN, Hulya; 55 Ross Hall Blvd. N., Piscataway, New
Jersey 08854 (US). **CROWLEY, Michael M.**; 13305
Council Bluff Drive, Austin, Texas 78727 (US).

(74) Agent: **SIEKMAN, Michael** et al.; c/o McDermott Will
& Emery LLP, 200 Clarendon Street, 58th Floor, Boston,
02116-5021 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: BEZUCLASTINIB FORMULATIONS




FIG. 1

(57) Abstract: The disclosure relates to formulations of bezuclastinib, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of c-Kit protein kinases and/or mutant c-kit protein kinases.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*